199 related articles for article (PubMed ID: 34765314)
21. Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer.
Luo C; Wang P; He S; Zhu J; Shi Y; Wang J
Front Oncol; 2022; 12():919072. PubMed ID: 35795050
[TBL] [Abstract][Full Text] [Related]
22. Plasmacytoid Dendritic Cell (pDC) Infiltration Correlate with Tumor Infiltrating Lymphocytes, Cancer Immunity, and Better Survival in Triple Negative Breast Cancer (TNBC) More Strongly than Conventional Dendritic Cell (cDC).
Oshi M; Newman S; Tokumaru Y; Yan L; Matsuyama R; Kalinski P; Endo I; Takabe K
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33198125
[TBL] [Abstract][Full Text] [Related]
23. [Expression of PTEN, p53 and EGFR in the molecular subtypes of breast carcinoma and
the correlation among them].
Li X; Wang Q; Fu L; Liu M; Yu X
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2015 Sep; 40(9):973-8. PubMed ID: 26408616
[TBL] [Abstract][Full Text] [Related]
24. A perspective on anti-EGFR therapies targeting triple-negative breast cancer.
Nakai K; Hung MC; Yamaguchi H
Am J Cancer Res; 2016; 6(8):1609-23. PubMed ID: 27648353
[TBL] [Abstract][Full Text] [Related]
25. Combined homologous recombination repair deficiency and immune activation analysis for predicting intensified responses of anthracycline, cyclophosphamide and taxane chemotherapy in triple-negative breast cancer.
Liao G; Jiang Z; Yang Y; Zhang C; Jiang M; Zhu J; Xu L; Xie A; Yan M; Zhang Y; Xiao Y; Li X
BMC Med; 2021 Sep; 19(1):190. PubMed ID: 34465315
[TBL] [Abstract][Full Text] [Related]
26. The clinical relevance of unfolded protein response signaling in breast cancer.
Oshi M; Roy AM; Gandhi S; Tokumaru Y; Yan L; Yamada A; Endo I; Takabe K
Am J Cancer Res; 2022; 12(6):2627-2640. PubMed ID: 35812054
[TBL] [Abstract][Full Text] [Related]
27. [Clinical features and prognosis of patients with first-episode liver metastasis of different molecular subtypes of breast cancer].
Wu SY; Tan Y; Guan YS
Zhonghua Gan Zang Bing Za Zhi; 2016 Jun; 24(6):422-8. PubMed ID: 27465945
[TBL] [Abstract][Full Text] [Related]
28. High expression of polo-like kinase 1 is associated with TP53 inactivation, DNA repair deficiency, and worse prognosis in ER positive Her2 negative breast cancer.
Takeshita T; Asaoka M; Katsuta E; Photiadis SJ; Narayanan S; Yan L; Takabe K
Am J Transl Res; 2019; 11(10):6507-6521. PubMed ID: 31737202
[TBL] [Abstract][Full Text] [Related]
29. Immune cytolytic activity is associated with reduced intra-tumoral genetic heterogeneity and with better clinical outcomes in triple negative breast cancer.
Oshi M; Kawaguchi T; Yan L; Peng X; Qi Q; Tian W; Schulze A; McDonald KA; Narayanan S; Young J; Liu S; Morris LG; Chan TA; Kalinski P; Matsuyama R; Otsuji E; Endo I; Takabe K
Am J Cancer Res; 2021; 11(7):3628-3644. PubMed ID: 34354864
[TBL] [Abstract][Full Text] [Related]
30. Investigating the clinical significance of EGFR expression using machine learning in a series of Iraqi patients with triple-negative breast cancer.
Salman G; Aldujaily E; Jabardi M; Qassid OL
J Med Life; 2022 Aug; 15(8):967-978. PubMed ID: 36188649
[TBL] [Abstract][Full Text] [Related]
31. Abundance of reactive oxygen species (ROS) is associated with tumor aggressiveness, immune response, and worse survival in breast cancer.
Oshi M; Gandhi S; Yan L; Tokumaru Y; Wu R; Yamada A; Matsuyama R; Endo I; Takabe K
Breast Cancer Res Treat; 2022 Jul; 194(2):231-241. PubMed ID: 35639264
[TBL] [Abstract][Full Text] [Related]
32. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry.
Park S; Koo JS; Kim MS; Park HS; Lee JS; Lee JS; Kim SI; Park BW
Breast; 2012 Feb; 21(1):50-7. PubMed ID: 21865043
[TBL] [Abstract][Full Text] [Related]
33. Subtype classification for prediction of prognosis of breast cancer from a biomarker panel: correlations and indications.
Chen C; Yuan JP; Wei W; Tu Y; Yao F; Yang XQ; Sun JZ; Sun SR; Li Y
Int J Nanomedicine; 2014; 9():1039-48. PubMed ID: 24591826
[TBL] [Abstract][Full Text] [Related]
34. Long-term treatment patterns and survival in metastatic breast cancer by intrinsic subtypes - an observational cohort study in Sweden.
Lindman H; Wiklund F; Andersen KK
BMC Cancer; 2022 Sep; 22(1):1006. PubMed ID: 36138404
[TBL] [Abstract][Full Text] [Related]
35. NRF1 motif sequence-enriched genes involved in ER/PR -ve HER2 +ve breast cancer signaling pathways.
Ramos J; Das J; Felty Q; Yoo C; Poppiti R; Murrell D; Foster PJ; Roy D
Breast Cancer Res Treat; 2018 Nov; 172(2):469-485. PubMed ID: 30128822
[TBL] [Abstract][Full Text] [Related]
36. Inflammation Is Associated with Worse Outcome in the Whole Cohort but with Better Outcome in Triple-Negative Subtype of Breast Cancer Patients.
Oshi M; Newman S; Tokumaru Y; Yan L; Matsuyama R; Endo I; Takabe K
J Immunol Res; 2020; 2020():5618786. PubMed ID: 33457427
[TBL] [Abstract][Full Text] [Related]
37. HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients.
Bae SY; La Choi Y; Kim S; Kim M; Kim J; Jung SP; Choi MY; Lee SK; Kil WH; Lee JE; Nam SJ
Breast Cancer Res Treat; 2013 Jun; 139(3):741-50. PubMed ID: 23722313
[TBL] [Abstract][Full Text] [Related]
38. No association between triple-negative breast cancer and prognosis of patients receiving breast-conserving treatment.
Mu L; Liu Y; Xiao M; Liu W; Liu M; Wang X
Oncol Lett; 2017 Dec; 14(6):7862-7872. PubMed ID: 29250179
[TBL] [Abstract][Full Text] [Related]
39. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
[TBL] [Abstract][Full Text] [Related]
40. Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel.
Fountzilas G; Dafni U; Bobos M; Batistatou A; Kotoula V; Trihia H; Malamou-Mitsi V; Miliaras S; Chrisafi S; Papadopoulos S; Sotiropoulou M; Filippidis T; Gogas H; Koletsa T; Bafaloukos D; Televantou D; Kalogeras KT; Pectasides D; Skarlos DV; Koutras A; Dimopoulos MA
PLoS One; 2012; 7(6):e37946. PubMed ID: 22679488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
